A target trial emulation in *Nature Medicine* (March 2026) followed 174,678 adults with type 1 diabetes in a US electronic health record network. Patients who initiated a GLP-1 receptor agonist had a five-year MACE risk of 4.3% versus 5.0% on standard care (HR 0.85, 95% CI 0.77–0.95), and a meaningful reduction in end-stage kidney disease. T1D was excluded from every landmark GLP-1 cardiovascular outcomes trial; this is the first large signal that the cardiorenal benefit travels into a population the original evidence base ignored. Observational, not randomized — the usual caveats apply, and the hypoglycemia and DKA signals from the older ADJUNCT trials still deserve attention. But for endocrinologists, nephrologists, and T1D registries, this is the kind of result that changes which questions get asked next.